We hypothesize that the antitumor effect(s) od chemotherapy are enhanced by responses to IL-2 and IFNalpha in human melanoma patients receiving biochemotherapy. This proposal is centered around the analysis of a randomized clinical trial which compares the efficacy of systemic biochemotherapy vs. chemotherapy alone for advanced malignant melanoma. Previous studies have suggested a >50% response from the biochemotherapy group, therefore, we expect to elucidate changes that are relevant to a successful therapeutic maneuver and which will provide insight into response mechanism(s). This R01 is complemented by two others, one which incorporates analysis of specific effects on the DNA of the patients during therapy, and the other studying human melanoma models for direct testing of agents. The working hypothesis of this proposal is that biotherapy stimulates tumor infiltrating macrophages and/or endothelia to produce oxidants which interfere with DNA repair in the tumor cells, thereby augmenting the effect of chemotherapy.
Aim 1 will determine whether systemic measurements of macrophage activation relate to pro-oxidant effects, and if either of these parameters correlate with DNA interstrand crosslinks and/or patient response to therapy. This will be accomplished by measuring neopterin (by RIA), measurements of monocyte activation, immunostaining for macrophages in the tumor, and plasma lipid peroxidation as an indicator of pro-oxidant production during the clinical trial. We further hypothesize that IL-1s are critical local mediators inducing the production of oxygen radicals, and that in some patients IL-1 may already be expressed by the tumor, while in others the biochemotherapy or chemotherapy induces production.
Aim 2 will test whether those patients whose tumors are producing Il-1alpha or IL-1beta are those patients most responsive to biochemotherapy or chemotherapy. Finally, using ELISA and immunohistology evaluation of the systemic and local presence of TNFalpha, IL-6, IFNlambda, and IL-8 will be performed. The final hypothesis is that an explanation for the variability of patient response to biochemotherapy or chemotherapy is due, in part, to the heterogeneity of multiple cytokine expression from the tumor itself.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA064906-01
Application #
2107640
Study Section
Special Emphasis Panel (SRC (72))
Project Start
1994-08-01
Project End
1998-05-31
Budget Start
1994-08-01
Budget End
1995-05-31
Support Year
1
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Biology
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Ekmekcioglu, S; Ellerhorst, J; Mhashilkar, A M et al. (2001) Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int J Cancer 94:54-9
Grimm, E A; Smid, C M; Lee, J J et al. (2000) Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin Cancer Res 6:3895-903
Ekmekcioglu, S; Ellerhorst, J; Smid, C M et al. (2000) Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 6:4768-75
Caudell, E G; Caudell, J J; Tang, C H et al. (2000) Characterization of human copine III as a phosphoprotein with associated kinase activity. Biochemistry 39:13034-43
Ekmekcioglu, S; Okcu, M F; Colome-Grimmer, M I et al. (1999) Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10. Melanoma Res 9:261-72
Anderson, C M; Buzaid, A C; Sussman, J et al. (1998) Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. Melanoma Res 8:149-55
Woods, K V; Adler-Storthz, K; Clayman, G L et al. (1998) Interleukin-1 regulates interleukin-6 secretion in human oral squamous cell carcinoma in vitro: possible influence of p53 but not human papillomavirus E6/E7. Cancer Res 58:3142-9
Woods, K V; El-Naggar, A; Clayman, G L et al. (1998) Variable expression of cytokines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens. Cancer Res 58:3132-41
Francis, G M; Krohn, E G; Woods, K V et al. (1996) Interleukin-6 production and secretion in human melanoma cell lines: regulation by interleukin-1. Melanoma Res 6:191-201
Tyler, D S; Francis, G M; Frederick, M et al. (1995) Interleukin-1 production in tumor cells of human melanoma surgical specimens. J Interferon Cytokine Res 15:331-40